Posted on

cbd oil and glioblastoma

Glioblastoma (GBM) or WHO grade IV astrocytoma is the most aggressive form of brain tumors and ranks among the deadliest types of cancer. It is also the most common malignant primary brain tumor. Its high proliferation rate and invasiveness, together with a considerable cellular and molecular heterogeneity, is a challenge for treatment. Current therapeutic strategies include surgery, chemotherapy, radiotherapy and combinations thereof. Temozolomid (TMZ) is considered as the benchmark for treatment but resistance to TMZ antitumoral action is frequent and contributes to the overall poor prognosis. After second line treatment with TMZ, median survival is around 5.1 to 13 months, depending on the study [1].

Anti-cancer effects of cannabinoids have long been argued. Scientific evidence goes back to 1974 at the Medical College of Virginia at the behest of the US government. In an attempt to provide data proving a link between cannabis and cancer risk in order to provide evidence justifying international prohibition, the contrary was observed [2]. With the detection of the endocannabinoid system in the early 90-ies, much insight was gained into the mechanisms of cannabinoids; a number of preclinical studies, in vitro as well as in vivo, confirmed the antineoplastic properties of both, phyto- and synthetic cannabinoids. Out of the phytocannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best studied substances. These two cannabinoids differ in their effective doses: Common oral doses of THC are in the order of two to three times 2.5 mg to 10 mg/day, whereas CBD is currently administered in a dose of 100 to 300mg twice daily; doses up to 1,500mg CBD have been well tolerated. THC has some inherent clinical drawbacks due to its psychotropic properties, in addition to increased anxiety and withdrawal symptoms after high doses and down-regulation of CB1 receptors [3,4]. In contrast, CBD is free from such constraints. Furthermore, THC is unsuited for children and adolescents. Although rare when compared with adults, brain tumors are the most common solid tumors in children.

Clinical Investigation Support GmbH, Kaiserstrasse, Austria

What are the perspectives of cannabidiol (CBD) for the treatment of glioblastoma?

cannabidiol, CBD, cannabinoids, delta-9-tetrahydrocannabinol, THC, glioblastoma

Cannabinoids demonstrate tumor-specific cytostatic/cytotoxic effects modulating the growth of glioblastoma by multiple, often overlapping mechanisms that repeatedly showed synergism when combined with other treatments. In particular CBD has been reported to activate apoptosis via oxidative stress (increase in ROS production in tumor cells [5]), and to inhibit tumor cell proliferation by inducing cell cycle arrest. Furthermore, CBD inhibits tumor angiogenesis and infiltration/ invasion even at low concentrations and abrogates resistance of glioma stem-like cells to BCNU (carmustine) therapy [6]. Cannabinoids are synergistic with chemotherapy and also with gamma-irradiation [7-9]. So far, experiments suggest that high doses of cannabinoids are necessary in order to achieve anti-tumor effects. In the inverse, low concentrations or doses respectively, may even enhance the growth of glioma, lung and breast cancer cells in vitro [10] and in vivo [11,12]. In addition to the tissue concentration and experimental conditions, effects depend very much upon the nature of the tumor cells. Although preclinical results cannot be transferred one-to-one to the situation in man, dose-dependency has been observed not only in vitro but also in animal experiments. A condensed overview on available in vivo results with CBD is presented in table 1.

Table 1. Results of CBD and CBD: THC combinations in animal models of glioma

The researchers believe that CBD’s anti-cancer actions target mitochondria—the cell’s energy producing structures—by causing the mitochondria to dysfunction and release harmful reactive oxygen species. Their experiments showed that cells treated with CBD exhibited significant decreases in mitochondrial activity.

The new work revealed that the toxic effects of CBD are mediated through the cell’s natural pathway for apoptosis, a form of programmed cell death. The researchers also observed that CBD-induced cell death was characterized by large, swollen intracellular vesicles before the membrane begins to bulge and breakdown. This was true for all the cell lines studied.

“Further research and treatment options are urgently needed for patients afflicted by brain cancer,” said Chase Gross, a student in the Doctor of Veterinary Medicine/Master of Science program at Colorado State University. “Our work shows that CBD has the potential to provide an effective, synergistic glioblastoma therapy option and that it should continue to be vigorously studied.”

Mr. Gross and colleagues examined human and canine glioblastoma cells because the cancer shows striking similarities between the two species. They tested the effects of CBD isolate, which contains 100 percent CBD, and CBD extract, which contains small amounts of other natural occurring compounds such as cannabigerol and tetrahydrocannabinol, or THC.

Experimental Biology is an annual meeting that attracts more than 12,000 scientists and exhibitors from five host societies and more than two dozen guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the U.S. and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. #expbio

Contact the media team for more information.

The study looked at glioblastoma, an often-deadly form of brain cancer that grows and spreads very quickly. Even with major advancements in treatment, survival rates for this cancer have not improved significantly.